Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 13 (Search time: 0.008 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cellsNievergall, E.; Ramshaw, H.; Yong, A.; Biondo, M.; Busfield, S.; Vairo, G.; Lopez, A.; Hughes, T.; White, D.; Hiwase, D.
2013STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent mannerSchafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; White, D.; Hughes, T.; Leclercq, T.
2013Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cellsHiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.
2010Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitorsHiwase, D.; White, D.; Powell, J.; Saunders, V.; Zrim, S.; Frede, A.; Guthridge, M.; Lopez, A.; D'Andrea, R.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.
2010Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapyHiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
2015Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemiaSchafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; Leclercq, T.; Hughes, T.; White, D.
2013Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsWhite, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
2018Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift studyHiwase, D.; Tan, P.; D'Rozario, J.; Taper, J.; Powell, A.; Irving, I.; Wright, M.; Branford, S.; Yeung, D.; Anderson, L.; Gervasio, O.; Levetan, C.; Roberts, W.; Solterbeck, A.; Traficante, R.; Hughes, T.
2016TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyNievergall, E.; Reynolds, J.; Kok, C.; Watkins, D.; Biondo, M.; Busfield, S.; Vairo, G.; Fuller, K.; Erber, W.; Sadras, T.; Grose, R.; Yeung, D.; Lopez, A.; Hiwase, D.; Hughes, T.; White, D.
2019Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remissionShanmuganathan, N.; Braley, J.; Yong, A.; Hiwase, D.; Yeung, D.; Ross, D.; Hughes, T.; Branford, S.